Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04181372

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer Clinical Trial

Official title:
A Phase II Study of Neoadjuvant Double-drug Chemotherapy With Platinum Plus Anlotinib Hydrochloride in Stage III(N2) Non-small-cell Lung Cancer

Clinical Trial Summary

Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant double-drug chemotherapy containing platinum plus anlotinib hydrochloride in patients with stage III(N2) non-small-cell lung cancer.

Clinical Trial Description

This is a prospective, open-label, multi-institutional, positive medicine control of equal rank comparative study of neoadjuvant double-drug chemotherapy with platinum plus anlotinib hydrochloride in stage III(N2) non-small-cell lung cancer.The main purpose of this study was to compare the difference in N2 downgrade rate of lymph node and resectability rate between the experimental and control groups, to evaluate the efficacy of anlotinib hydrochloride, and to observe and evaluate its objective response rate(ORR)，Disease-free Survival (DFS)and overall survival(OS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04181372
Study type Interventional
Source The First Affiliated Hospital of Guangzhou Medical University
Contact Jiexia Zhang, prof.
Phone +8613903056432
Email drzjxcn@126.com
Status Not yet recruiting
Phase Phase 2
Start date December 2019
Completion date August 1, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04085250 - Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Completed NCT01733589 - Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC Phase 1/Phase 2
Recruiting NCT04325763 - A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) Phase 3
Active, not recruiting NCT03589547 - Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Phase 2
Not yet recruiting NCT04304638 - Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Active, not recruiting NCT01576796 - Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer Phase 2
Recruiting NCT04441138 - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC Phase 2
Terminated NCT03871153 - Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer Phase 2
Completed NCT05331833 - Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.